Pfizer’s CEO says a THIRD Covid vaccine dose will be needed within six months

0

BREAKING NEWS: Pfizer CEO Says A THIRD Covid Vaccine Dose Will Be Necessary Once Someone Is Vaccinated Six Months After Someone Has Two Injections – Then Annually

  • Pfizer CEO Albert Bourla said it’s ‘likely’ people will need a booster shot of the COVID-19 vaccine
  • The possible booster shot will be given within 12 months of someone being fully vaccinated
  • Bourla said people may need to be immunized against the new coronavirus every year

The Pfizer Inc CEO says he believes people will likely need a third dose of the COVID-19 vaccine.

In a panel discussion hosted by CNBC in partnership with CVS Health on Thursday, Albert Bourla said a possible booster shot would be administered six to 12 months after full vaccination.

Bourla added that he thinks it is possible that people may need to be vaccinated against the coronavirus every year.

“It is extremely important to suppress the pool of people who may be susceptible to the virus,” he said.

Pfizer CEO Albert Bourla said it's 'likely' people will need a booster shot of the COVID-19 vaccine

Pfizer CEO Albert Bourla said it’s ‘likely’ people will need a booster shot of the COVID-19 vaccine

Pfizer and its German partner BioNTech began studying a third dose of their vaccine in late February.

The booster shot is designed to protect against future variants, which may be better at evading antibodies from the vaccine than previous strains of the virus.

About 144 volunteers will receive the third dose, mostly those who participated in the early US testing of the vaccine last year.

The vaccine uses part of the pathogen’s genetic code, called messenger RNA, or mRNA, to make the body recognize the coronavirus and attack it if a person becomes infected.

In the shot, known as BNT162b2, the mRNA encodes all of the spike protein found on the outside of the virus that it uses to invade and infect cells.

It was approved for emergency use by the U.S. Food and Drug Administration (FDA) after a clinical trial of 44,000 volunteers determined that the injection was 95 percent effective in preventing symptomatic COVID-19.

Field data six months later showed that the vaccine offered 91 percent protection six months later.

However, the company’s current two-dose regimen caused a weaker immune response to the South African variety.

This is a breaking news story and will be updated.

Advertisement